Equity Profile

GMED

Globus Medical, Inc.

Health CareHealth Care Equipment$10.9B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:15 PM EDT

Globus Medical Beats on EPS, Stock Down 4.65%

Metric	Actual	Expected	Surprise
EPS	$1.12	$0.92	+22.00%
Revenue	—	$741M	—

management commentary, guidance changes, and full analysis available with Pro.

Globus Medical Beats on EPS, Stock Down 4.65%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.12	$0.92	+22.00%
Revenue	—	$741M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Globus Medical reported better-than-expected earnings per share, surpassing analyst estimates by 22%. However, the stock fell by 4.65% on the day, indicating that investors may have been disappointed by the lack of revenue information and guidance. The absence of a management commentary could also contribute to uncertainty among investors.

Company Snapshot

Globus Medical, Inc. (GMED) is a leading medical device company focused on developing innovative solutions for spinal surgery....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$0.92

Revenue

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for long-term success.

$741M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Globus Medical, Inc. (GMED) is a leading medical device company focused on developing innovative solutions for spinal surgery. Operating in the Health Care Equipment sector, it plays a crucial role in improving patient outcomes through advanced technology and surgical techniques.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+15.40%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q4-2025, Globus Medical reported an EPS of $1.28, significantly exceeding estimates by 20.41%. However, the stock saw a slight decline of 1.63% the following day.

Management Promises & Guidance

Continued focus on innovation in spinal surgery solutions.
Commitment to expanding market share in the health care equipment sector.
Plans to enhance operational efficiency and reduce costs.

Expectations

Wall Street Expectations

Analysts expect a solid performance from Globus Medical in Q1-2026, with a consensus EPS of $0.92 and revenue of $741M. The market is closely watching how the company will navigate potential challenges in the health care sector.

Bull Case

If the company can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products and lead to a positive market reaction.

Bear Case

Conversely, if the company misses its EPS or revenue targets, it may raise concerns about its growth trajectory and competitive positioning, potentially leading to a negative stock reaction.

Key Metrics to Watch

EPS

$0.92

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$741M

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for long-term success.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $0.92?

A beat on EPS would reinforce investor confidence in the company's profitability and operational efficiency.

What are the revenue expectations in light of market conditions?

Revenue performance is crucial for assessing the company's growth potential and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the company's ability to capitalize on recent innovations in spinal surgery, leading to stronger-than-expected revenue growth.

Supporting Evidence

Recent earnings history shows a consistent ability to beat EPS estimates, suggesting potential for another surprise.

The options market indicates a larger expected move than historical averages, hinting at possible positive sentiment.

Management's previous commitments to innovation may not be fully reflected in current estimates.

Key Risk

If revenue growth exceeds $785M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will provide insights into the company's ability to sustain growth amidst competitive pressures.

Bull Confirmed If

An EPS of $1.06 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $0.80 would signal potential weaknesses in profitability and market challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±8.7%

Historical Avg

±1.35%

Pricing rich

The options market is pricing in a significant move of approximately 8.7% around the earnings report, suggesting heightened volatility expectations.

Options are pricing a larger move than the historical average, indicating that traders expect more volatility than usual.

Detail

ATM IV

1.1%

30d HV

33.3%

Calls (4K)P/C Ratio: 1.72Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 3.3%, with a raw directional average of +2.1% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GMED beats expectations, history suggests the stock could rise by approximately 0.89%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 1.33%, raising concerns about the company's growth trajectory.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on sales.
2Insights into market demand trends for spinal surgery solutions.
3Management's commentary on operational efficiencies and cost management.
4Details on competitive positioning and market share growth.
5Any guidance on future revenue expectations and strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

APLEReported

Apple Hospitality REIT, Inc.

RecapView

May4

CRBGReported

Company Snapshot

Globus Medical, Inc. (GMED) is a leading medical device company focused on developing innovative solutions for spinal surgery....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$0.92

Revenue

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for long-term success.

$741M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+15.40%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q4-2025, Globus Medical reported an EPS of $1.28, significantly exceeding estimates by 20.41%. However, the stock saw a slight decline of 1.63% the following day.

Management Promises & Guidance

Continued focus on innovation in spinal surgery solutions.
Commitment to expanding market share in the health care equipment sector.
Plans to enhance operational efficiency and reduce costs.

Expectations

Wall Street Expectations

Bull Case

If the company can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products and lead to a positive market reaction.

Bear Case

Conversely, if the company misses its EPS or revenue targets, it may raise concerns about its growth trajectory and competitive positioning, potentially leading to a negative stock reaction.

Key Metrics to Watch

EPS

$0.92

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$741M

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for long-term success.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $0.92?

A beat on EPS would reinforce investor confidence in the company's profitability and operational efficiency.

What are the revenue expectations in light of market conditions?

Revenue performance is crucial for assessing the company's growth potential and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the company's ability to capitalize on recent innovations in spinal surgery, leading to stronger-than-expected revenue growth.

Supporting Evidence

Recent earnings history shows a consistent ability to beat EPS estimates, suggesting potential for another surprise.

The options market indicates a larger expected move than historical averages, hinting at possible positive sentiment.

Management's previous commitments to innovation may not be fully reflected in current estimates.

Key Risk

If revenue growth exceeds $785M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will provide insights into the company's ability to sustain growth amidst competitive pressures.

Bull Confirmed If

An EPS of $1.06 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $0.80 would signal potential weaknesses in profitability and market challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±8.7%

Historical Avg

±1.35%

Pricing rich

The options market is pricing in a significant move of approximately 8.7% around the earnings report, suggesting heightened volatility expectations.

Options are pricing a larger move than the historical average, indicating that traders expect more volatility than usual.

Detail

ATM IV

1.1%

30d HV

33.3%

Calls (4K)P/C Ratio: 1.72Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 3.3%, with a raw directional average of +2.1% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GMED beats expectations, history suggests the stock could rise by approximately 0.89%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 1.33%, raising concerns about the company's growth trajectory.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on sales.
2Insights into market demand trends for spinal surgery solutions.
3Management's commentary on operational efficiencies and cost management.
4Details on competitive positioning and market share growth.
5Any guidance on future revenue expectations and strategic initiatives.